

TRANSFORMATIONS OF 4-N-ARYLAMINO-4-(8-QUINOLINYL)-1-BUTENES AND 3-ARYL-2-(8-QUINOLINYL)-4-THIAZOLIDINONES

Leonor Y. Vargas Méndez^a, Vladimir Kouznetsov^a, Juan C. Poveda^a, Cigdem Yolaçan^b, Nüket Öcal^b, and Feray Aydoğan^b

^a -Research Center for Biomolecules, Laboratory of Fine Organic Synthesis, School of Chemistry, Industrial University of Santander, A.A. 678, Bucaramanga, Colombia

^b -Department of Chemistry, Yildiz Technical University, Davutpasa Campus, 34210 Istanbul, Turkey

Abstract: The chemistry of 4-N-arylamino-4-(8-quinoliny)-1-butenes **1-5** and 3-aryl-2-(8-quinoliny)-4-thiazolidinones **15** has been studied. N-Furoylation, N-allylation, mediated-acid intramolecular cyclization, amino-Claisen transposition and aldol reactions were used to prepare new C-8 substituted quinolines with biological potential.


Introduction

Quinolines belong to an important group of natural products containing a heterocyclic ring. Moreover, a large number of quinoline derivatives are used in the pharmaceutical industry for a wide range of biological purposes like several parasitical drugs that are based on the 8-aminosubstituted quinoline nucleus¹⁻³. Diverse biological activities have been associated with thiazolidinone derivatives⁴⁻⁷. We recently reported the synthesis of 4-N-arylamino-4-(8-quinoliny)-1-butenes and 3-aryl-2-(8-quinoliny)-4-thiazolidinones from quinoline-8-carbaldehyde, via formation of Schiff bases and further allylation or cyclocondensation of mercapto acids^{8,9}. The biological significance of this class of compounds encouraged us to develop these C-8 substituted quinolines with possible biological activity. As part of our research program on the chemistry of homoallylamines and thiazolidinones with a quinoline ring, we wish to report here some transformations of 4-N-arylamino-4-(8-quinoliny)-1-butenes and 3-aryl-2-(8-quinoliny)-4-thiazolidinones.

Results and Discussion


Chemical transformations of 4-N-arylamino-4-(8-quinoliny)-1-butenes **1-5** are shown in Scheme 1. Quinoline **3** was prepared from 8-[N-(p-ethoxyphenyl)formimidoyl]quinoline using an C-allylation reaction⁹. The treatment of aminobutenes **3,4** with α -furoyl chloride in the presence of Et₃N in dry benzene gave the respective quinoline amides **6** and **7** in 63-67% yields. The N-allylation of quinoline aminobutenes **1,2** was

carried out with allyl bromide in the presence of K_2CO_3 in dry acetone affording the derivatives **8**⁹ and **9**, which are used in the amino-Claisen rearrangement¹⁰. Under the conditions of this transformation (heating in $BF_3 \cdot OEt_2$), the N-allylated derivative **9** gave a rearranged product **10** in 60% yield, meanwhile similar heating of product **8** afforded two different compounds: a rearranged product **11** (52%) and a quinoline **12** with the tricyclic lilolidine structure (42%). Intramolecular allyl cyclisation of the aminobutenes **3,5** was readily achieved heating these compounds in 82% H_2SO_4 producing the 4-methyl-2-(8-quinolinyl)-1,2,3,4-tetrahydroquinolines **13,14** in 35-76% yields. The final products were purified by column chromatography on alumina. The structural assignments proposed for the C-8 substituted quinolines **6-14** were consistent with their IR, 1H - and ^{13}C -NMR spectra and were supported by the mass spectrometric data.



Scheme 1

Seeking substances with potential bioactivity among other series of C-8 substituted quinolines, we performed an aldol condensation reaction of 3-aryl-2-(8-quinolinyl)-4-thiazolidinones (Scheme 2).



Scheme 2

The 5-arylidene thiazolidinone derivatives **16a-i** were synthesised from 3-(4-methylphenyl)- and 3-(4-methoxyphenyl)-2-(8-quinolinyl)-4-thiazolidinones (**15a,b**) that were obtained by a known procedure⁹ and allowed to react with different aromatic aldehydes in the presence of sodium ethoxide to afford the final α,β -

cones **16**, which showed in the IR spectra the characteristic C=O bands appearing in the region of 1676-1660 cm^{-1} . The ^1H NMR spectra of compounds **15a,b** displayed characteristic AB doublets at δ 3.77-4.06 ppm (5- CH_2). In the condensation products, this AB system was absent confirming that an aldol condensation had taken place.

Experimental

Melting points are uncorrected and were measured in open capillaries with an Electrothermal IA 9100 melting point apparatus. Infrared spectra were recorded on a Perkin Elmer 599B-FT (compounds **6-14**) and on a Philips PU 9714 (compounds **15,16**) spectrometers as KBr pellets unless otherwise indicated. NMR spectra were determined on a Bruker AM-400 (compounds **6-14**) and on a Nicolet 300 MHz (compounds **15,16**) spectrometers in CDCl_3 with TMS as internal standard. Their mass spectra were obtained with a Shimadzu GS/MS QP 2000A spectrometer with 70 eV electron impact ionization. Elemental analyses were performed on a Leco CHN-600 analyzer. Column chromatography was performed with silica gel 60 (70-230 mesh) and aluminium oxide 90 active neutral (70-230 mesh). Elemental analyses were in satisfying agreement with the calculated data. Preparation of aminobutene **3** and N-furoylation or N-allylation of aminobutenes **1-5** were effectuated by the known procedures⁹.

3: yield 65%; a pale yellow viscous oil; IR (KBr): $\nu = 3404, 1639 \text{ cm}^{-1}$; ^1H NMR (400 MHz, CDCl_3): δ 8.55-6.92 (6H, m, quinoline), 6.67-6.53 (4H, AA'BB'-system, Ar), 5.94-5.82 (1H, m, =CH), 5.20-5.08 (2H, m, = CH_2), 3.87 (2H, q, $J = 6.9 \text{ Hz}$, OCH_2CH_3), 3.05 and 2.72 (1H, each, m, 3- CH_2 , H_A and H_B), 2.05 (1H, dd, $J = 7.0 \text{ Hz}$, 4-CH), 1.32 (3H, t, $J = 6.9 \text{ Hz}$, OCH_2CH_3) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 154.7-114.9 (quinoline and phenyl), 132.2 (=CH), 117.3 (= CH_2), 64.0 (OCH_2), 55.2 (4-CH), 41.7 (3- CH_2), 15.1 (CH_3) ppm; MS: $m/z = 318 (\text{M}^+)$.

6: yield 63%; m.p. 89-90°C; IR (KBr): $\nu = 1635, 1600 \text{ cm}^{-1}$; ^1H NMR (400 MHz, CDCl_3): δ 7.91-7.17 (7H, m, quinoline and α' -Fu), 6.53-6.49 (4H, AA'BB'-system, Ar), 5.99 (1H, s, β' -Fu), 5.97-5.90 (1H, m, =CH), 5.24 (1H, s, β -Fu), 5.14-4.96 (2H, m, = CH_2), 3.84 (2H, q, $J = 6.9 \text{ Hz}$, OCH_2CH_3), 3.07 and 2.84 (1H, each, m, 3- CH_2 , H_A and H_B), 1.85 (1H, dd, $J = 6.9 \text{ Hz}$, 4-CH), 1.27 (3H, t, $J = 6.9 \text{ Hz}$, OCH_2CH_3); ^{13}C NMR (100 MHz, CDCl_3): δ 161.9 (C=O), 158.3-121.3 (quinoline and phenyl), 143.7 (α' -Fu), 136.2 (α -Fu), 135.8 (=CH), 117.1 (= CH_2), 115.2 (β -Fu), 110.6 (β' -Fu), 63.4 (OCH_2), 40.9 (3- CH_2), 18.5 (4-CH), 14.6 (CH_3); MS: $m/z = 412 (\text{M}^+)$.

7: yield 67%; a pale yellow viscous oil; IR (neat): $\nu = 1651, 1600 \text{ cm}^{-1}$; ^1H NMR (400 MHz, CDCl_3): δ 7.92-7.18 (7H, m, quinoline and α' -Fu), 6.48-6.44 (4H, AA'BB'-system, Ar), 6.06 (1H, s, β' -Fu), 6.00-5.87 (1H, m, =CH), 5.62 (1H, s, β -Fu), 5.16-4.99 (2H, m, = CH_2), 3.09 and 2.89 (1H, each, m, 3- CH_2 , H_A and H_B), 1.85 (1H, dd, 4-CH; $J = 6.7 \text{ Hz}$); ^{13}C NMR (100 MHz, CDCl_3): δ 162.1 (C=O), 155.3-119.4 (quinoline and

phenyl), 143.9 (α' -Fu), 135.6 (α -Fu), 135.4 (=CH), 117.3 (=CH₂), 115.9 (β -Fu), 110.7 (β' -Fu), 40.8 (3-CH₂), 18.5 (4-CH); MS: m/z = 402 (M^+ for ³⁵Cl).

9: yield 80%; a pale red oil; IR (neat): ν = 1599, 915 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.96-7.22 (6H, m, quinoline), 6.82-6.65 (4H, AA'BB'-system, Ar), 5.80-5.52 (2H, m, CH=), 5.05-4.88 (4H, m, CH₂=), 3.86 (2H, m, N-CH₂), 3.60 (3H, s, OCH₃), 2.78 (2H, m, CH₂-allyl), 1.79 (1H, dd, J = 6.6 Hz, N-CH-Qu); ¹³C NMR (100 MHz, CDCl₃): δ 149.2-113.9 (quinoline and phenyl), 136.2, 136.1 (=CH), 116.2, 115.5 (=CH₂), 55.5 (OCH₃), 50.6 (N-CH₂), 36.9 (CH₂-allyl), 18.4 (N-CH-Qu); MS: m/z = 303 ($M-C_3H_5$)⁺.

Amino-Claisen rearrangement of N-allyl substituted aminobutenes 8 and 9. General procedure.

The aminobutenes **8,9** (0.003 mol) was heated to reflux for 8-10 h in BF₃Et₂O (2.0 ml), cooled and poured into ice. The pH was brought to 8 with Na₂CO₃. The organic products were extracted with CH₂Cl₂ (3×10 ml). The combined extracts were dried (Na₂SO₄) and concentrated. The oily residue was purified by column chromatography (Al₂O₃, heptane/ethyl acetate, from 25:1 to 20:1) to afford the compounds **10-12**.

10: yield 60%; a viscous brownish liquid; IR (neat): ν = 3415 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 7.96-6.23 (9H, m, quinoline and Ar), 5.94 and 5.71 (1H, each, m, -CH=), 5.11 and 4.83 (2H, each, m, CH₂=), 3.92-3.73 (2H, m, -CH₂-allyl), 3.57 (3H, s, OCH₃), 2.92-2.78 (2H, m, 3-CH₂), 1.94 (1H, d, J = 6.7 Hz, 4-CH); ¹³C NMR (100 MHz, CDCl₃): δ 154.9-111.8 (quinoline and phenyl), 136.3 and 135.8 (=CH), 116.2 and 115.3 (=CH₂), 55.6 (OCH₃), 49.5 and 36.9 (-CH₂-allyl), 18.5 (4-CH) ppm; MS: m/z = 303 ($M-C_3H_5$)⁺.

11: yield 52%; a viscous pale yellow liquid; IR (neat): ν = 3414 cm⁻¹; ¹H NMR (90 MHz, CDCl₃): δ 8.08-6.29 (9H, m, quinoline and Ar), 5.99 and 5.58 (1H, each, m, -CH=), 5.22 and 5.08 (2H, each, m, CH₂=), 3.39 (2H, m, -CH₂-allyl), 3.34 (2H, m, 3-CH₂), 2.77 (3H, s, CH₃), 2.18 (1H, d, J = 5.9 Hz, 4-CH); MS: m/z = 287 ($M-C_3H_5$)⁺.

12: yield 42%; a viscous yellow liquid; ¹H NMR (300 MHz, CDCl₃): δ 6.70-8.12 (8H, m, quinoline and Ar), 5.82-5.76 (1H, m, 4-H), 5.09 and 4.69 (1H, each, m, 2-CH₂, H_A and H_B), 3.41-3.56 (1H, m, 6-H), 2.82-2.78 (1H, m, 1-CH₃), 2.41 and 1.85 (1H, each, m, 5-CH₂, H_A and H_B), 2.16 (3H, s, 8-CH₃), 1.78 (3H, d, J = 4.2 Hz, 1-CH₃), 1.49 (3H, d, J = 6.8 Hz, 6-CH₃) ppm; MS: m/z = 328 (M^+).

Intramolecular acid cyclisation of quinoline aminobutenes 3 and 5. General procedure.

To a stirred and cooled (0 °C) solution of aminobutenes **3,5** (1.0 g) and chloroform (2.0 mL) was added dropwise during 5 min 4.0 mL of concentrated sulfuric acid. The reaction mixture was heated at 95 °C and vigorously stirred for three hours and monitored by TLC. The reaction mixture was neutralized with a concentrated solution of ammonium hydroxide (pH \approx 9-10) in the cold, extracted with dichloromethane (3×20 mL), and purified by column chromatography, to gave the corresponding tetrahydroquinolines **13** and **14**.

13: yield 35%; a red oil; IR (neat): ν = 3353 cm⁻¹; ¹H NMR (90 MHz, CDCl₃): δ 8.43-6.59 (9H, m, quinoline and Ar), 5.68 (1H, dd, J = 7.6 Hz, 2-H), 4.02 (2H, q, J = 6.8 Hz, OCH₂CH₃), 3.45-3.23 (1H, m, 4-H), 2.25

and 1.85 (1H, each, m, 3-CH₂, H_A and H_B), 2.00 (3H, d, J = 6.7 Hz, 4-CH₃), 1.43 (3H, t, J = 6.8 Hz, OCH₂CH₃) ppm; MS: *m/z* = 318 (M⁺).

14: yield 76%; a orange crystals; m.p. 80-81°C; IR (KBr): ν = 3354 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 8.07-6.68 (8H, m, quinoline and Ar), 5.66 (1H, dd, J = 7.4 Hz, 2-H), 4.60 (1H, br.s, N-H), 3.37-3.28 (1H, m, 4-H), 2.43 and 1.98 (1H, each, m, 3-CH₂, H_A and H_B), 2.27, 2.08 (3H, each, s, 6/8-CH₃), 1.42 (3H, d, J = 6.7 Hz, 4-CH₃) ppm. ¹³C NMR (125 MHz, CDCl₃): δ 145.9, 141.5, 136.6, 132.5, 132.3, 128.7, 127.1, 126.7, 126.4, 126.0, 125.9, 125.8, 125.3, 122.0, 119.0, 50.6, 38.8, 31.4, 20.9, 18.6, 17.5 ppm; MS: *m/z* = 302 (M⁺).

Preparation of 3-aryl-5-arylidene-2-(8-quinolinyl)-4-thiazolidinones 16a-i. General procedure.

Equimolar solutions of 15a or 15b (0.01 mol) and the appropriate aromatic aldehyde (0.01 mol) in dry benzene (25 ml) in the presence of sodium ethoxide, were refluxed for about 10-12 h. The reaction mixture was cooled and poured into ice cold water, acidified with glacial acetic acid and the benzene layer separated. The solution was dried (CaCl₂) and evaporated in vacuo. The crude product was crystallized from petroleum ether : diethyl ether (1:1) to give yellow crystals.

16a: yield 55%; m.p. 153-4°C; IR (KBr): ν = 1660 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.99-7.21 (16H, m, quinoline, phenyl and 2-CH), 7.08 (1H, d, =CH), 2.24 (3H, s, CH₃); ¹³C NMR (75 MHz, CDCl₃): δ 166.9 (C=O), 150.2-121.8 (quinoline and phenyl), 58.4 (2-CH), 22.1 (CH₃); MS: *m/z* = 408 (M⁺).

16b: yield 70%; m.p. 170-2°C; IR (KBr): ν = 1660 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.87-7.13 (16H, m, quinoline, phenyl and 2-CH), 6.70 (1H, d, =CH), 3.57 (3H, s, OCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 167.3 (C=O), 158.3-114.8 (quinoline and phenyl), 58.4 (2-CH), 55.9 (OCH₃); MS: *m/z* = 424 (M⁺).

16c: yield 51%; m.p. 150-1°C; IR (KBr): ν = 1676 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.85-7.13 (15H, m, quinoline, phenyl and 2-CH), 7.05 (1H, d, =CH), 2.23 (3H, s, CH₃); ¹³C NMR (75 MHz, CDCl₃): δ 166.8 (C=O), 150.3-106.3 (quinoline and phenyl), 58.7 (2-CH), 21.3 (CH₃); MS: *m/z* = 442 (M⁺ for ³⁵Cl).

16d: yield 66%; m.p. 163-5°C; IR (KBr): ν = 1665 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.87-7.23 (15H, m, quinoline, phenyl and 2-CH), 6.71 (1H, d, =CH), 3.62 (3H, s, OCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 166.9 (C=O), 158.1-114.6 (quinoline and phenyl), 58.7 (2-CH), 55.7 (OCH₃); MS: *m/z* = 458 (M⁺ for ³⁵Cl).

16e: yield 59%; m.p. 153°C; IR (KBr): ν = 1676 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 8.91-6.99 (15H, m, quinoline, phenyl and 2-CH), 6.78 (1H, d, =CH), 3.72 (3H, s, OCH₃), 2.23 (3H, s, CH₃) ppm; ¹³C NMR (75 MHz, CDCl₃): δ 167.3 (C=O), 159.8-109.3 (quinoline and phenyl), 58.5 (2-CH), 55.6 (OCH₃), 21.2 (CH₃); MS: *m/z* = 438 (M⁺).

16f: yield 55%; m.p. 163°C; IR (KBr): ν = 1660 cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ 9.01-6.86 (15H, m, quinoline, phenyl and 2-CH), 6.81 (1H, d, =CH), 3.79 (3H, s, OCH₃), 3.71 (3H, s, OCH₃); ¹³C NMR (75 MHz, CDCl₃): δ 167.6 (C=O), 160.1-109.0 (quinoline and phenyl), 58.9 (2-CH), 56.2 (OCH₃), 56.0 (OCH₃); MS: *m/z* = 454 (M⁺).

16g: yield 70%; m.p. 175-6°C; IR (KBr): $\nu = 1660 \text{ cm}^{-1}$; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 9.08-7.06 (15H, m, quinoline, phenyl and 2-CH), 6.67 (1H, d, =CH), 2.95 (6H, s, $\text{N}(\text{CH}_3)_2$), 2.24 (3H, s, CH_3); $^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ 170.3 (C=O), 150.5-122.2 (quinoline and phenyl), 61.1 (2-CH), 34.2 ($\text{N}(\text{CH}_3)_2$), 21.4 (CH_3); MS: $m/z = 451 (\text{M}^+)$.

16h: yield 72%; m.p. 170-1°C; IR (KBr): $\nu = 1670 \text{ cm}^{-1}$; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 8.93-7.25 (15H, m, quinoline, phenyl and 2-CH), 6.74 (1H, d, =CH), 3.69 (3H, s, OCH_3), 2.98 (6H, s, $\text{N}(\text{CH}_3)_2$); $^{13}\text{C NMR}$ (75 MHz, CDCl_3): δ 169.3 (C=O), 150.5-112.2 (quinoline and phenyl), 61.1 (2-CH), 55.8 (OCH_3), 34.2 ($\text{N}(\text{CH}_3)_2$); MS: $m/z = 467 (\text{M}^+)$.

16i: yield 46%; m.p. 166°C; IR (KBr): $\nu = 1660 \text{ cm}^{-1}$; $^1\text{H NMR}$ (300 MHz, CDCl_3): δ 9.05-7.01 (15H, m, quinoline, phenyl and 2-CH), 6.95 (1H, d, =CH), 2.26 (3H, s, CH_3); MS: $m/z = 424 (\text{M}^+)$.

Acknowledgements

This work was supported by the grant of the Colombian Institute for Science and Research (COLCIENCIAS, project: 1102-05-110-97). Collaboration from RIIDMED (Iberoamerican Network on Investigation and Development of Medicines) of the Iberoamerican Program of Science and Technology for the Development (CYTED), are gratefully acknowledged. N.O. thanks Dr. Ihsan Erden, San Francisco State University for NMR and mass spectra and helpful discussions.

References

- 1 Lednicer D., Mitscher L. A., *The Organic Chemistry of Drug Synthesis*, John Wiley & Sons, New York 1977, V.1, pp 337.
- 2 Chiari E., Oliveira A.B., Prado M. A. F., Alves R. J., Galvão L. M. C., Araujo F. G., *Antimicrob. Agents Chemother.*, **40**, 613 (1996).
- 3 Armer R. E., Barlow J.S., Dutton C.J., Greenway D. H. J., Greenwood S. D. W., Lad N., Tommasini I., *Bioorg. Med. Chem. Lett.*, **20**, 2585 (1997).
- 4 Raasch M. S., *J. Heterocycl. Chem.*, **11**, 587 (1974).
- 5 Singh V. P., Parmar S. S., Raman K., Stenberg V., *Chem. Rev.*, **81**, 175 (1981).
- 6 Singh V. P., Upadhyay G. S., Singh H., *Asian J. Chem. Rev.*, **3**, 12 (1992).
- 7 Abdou W. M., Yakout El-Sayed M. A., Ganoub N. A. F., *Tetrahedron*, **51**, 11411 (1995).
- 8 Kouznetsov V., Öcal N., Turgut Z., Zubkov F., Kaban S., Varlamov A. V., *Monatsh. Chem.*, **129**, 671 (1998).
- 9 Öcal N., Yolacan C., Kaban S., Vargas L. Y., Kouznetsov V., *J. Heterocycl. Chem.*, **38**, (2001), in press.
- 10 Lutz R. P., *Chem. Rev.*, **84**, 205 (1984).

Received on March 3, 2001